BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

Hey Psychedelic Investors! There's been so much news this week that we decided to split "This Week In Psychedelic Stocks" in 2 parts. Part Deux: " BIG MindMed MDMA Trial, Atai's to Compete with Tesla's Neuralink (+Updates on CMPS, MYCO and ENBI)" might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: "HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?" That is if you are interested in the general developments in the psychedelic industry for this week. In this episode, there's lots of news for the psychedelic industry writ large. We'll start up with three different studies that were released in the first week of April. 1. We'll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ] 2. Atai Life Sciences' Computer Brain Interface & their clinical trial to treat Schizophrenia 3. Compass Pathways (CMPS) has amazing new price targets 4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials 5. Entheon's (ENBI / ENTBF) new Genetic Test Kit Updates ​... ​Timestamps: 0:00​ - Intro 1:47 - MindMed's (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing 6:08 - Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder 8:00 - Atai's Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia 9:07 - Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update 10:32 - Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 ) 13:02 - Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen's Psychedelics' Genetic KIT So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We'll try to cover most of them but if there's a company you want us to cover more in debt, please let us know in the comments and we'll try to satisfy your demands. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#MMEDStock #CMPS Stock

HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]

Hey Psychedelic Investors! There's been so much news this week that we decided to split "This Week In Psychedelic Stocks" in 2 parts. This segment is entitled "HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?" for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more. In this episode, there's lots of news for the psychedelic industry writ large. We'll start up with three different studies that were released in the first week of April. 1. The Effects of Treating Depression with Psilocybin 2. Taking Psychedelics in a Ritual Setting 3. Microdosing study After covering the pertinent aspects of these studies, we'll take a look at Americans' ability to buy Horizons' ETF and finally we'll give you some updates on some decriminalization efforts. So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel ​... ​Timestamps: 0:00​ - Intro 1:24 - Effects of Treating Depression with Psilocybin 4:03 - Effects of Taking Psychedelics in A Ritual Setting 7:23 - Exploring the relationship between microdosing, personality & emotional insight 9:36 - Americans May be able to invest in Horizon's ETF 11:42 - Progress on California's bill that would LEGALIZE Possession of Psychedelics 12:57 - Massachusetts Approves Psychedelics Decimalization General thoughts. We've been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it'll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​​ ​#psychedelics​​​​ #shroomboom
Psychedelic Business News Spotlight: April 9, 2021

Psychedelic Business News Spotlight: April 9, 2021

This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.

NUMI Stock Deep Dive [ Will Numinus Wellness be a Leader in The Shroom BOOM?] 🤔

What's up psychedelic investors! Today we're finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don't want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF. In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom! Time Stamps 0:00 - Intro 1:20 - What Problem is Numinus trying to solve? 3:22 - NuMi Ketamine Treatments for Depression 4:50 - MDMA to treat PTSD 6:24 - Numinus Wellness Treating Addiction with Psilocybin 7:48 - Special Access Trials for MDMA and Psilocybin 9:02 - Psilocybin Extraction from Magic Mushrooms 9:39 - Financials and Cash on Hand 11:29 - Risks https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021 So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! If you want to collaborate, send us an email! thepsychedelicinvestor@gmail.com Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifa ​... ​ https://benzinga.grsm.io/thepsychedel ​... ​ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #NuminusWellness #NUMIStock #MindMed
Mydecine Prepares to Present Four Novel Psychedelic Candidates

Mydecine Prepares to Present Four Novel Psychedelic Candidates

,
Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.

Entheon Biomedical CEO Interview With Timothy Ko | (CSE: ENBI) (OTC: ENTBF) | DMT Vs. Psilocybin

Entheon Biomedical CEO Timothy Ko (CSE: ENBI) (OTC: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction with DMT. Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception. Entheon Biomedical is developing a DMT-assisted therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives. Entheon's DMT clinical trial later this year will put it in direct competition with MindMed (MMED /MMEDF), who is also planning on launching a DMT clinical trial later this year. I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor For any potential collaborations, please reach us at: thepsychedelicinvestor@gmail.com Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video. https://entheonbiomedical.com/ CSE: ENBI | OTCQB: ENTBF This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/ #EntheonBiomedical​​​ ​#Entheon​​​ #PsychedelicStocks

MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]

In today's episode of "This Week in Psychedelic Stocks", we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) , Core One Labs ( COOL) & Lobe Sciences (LOBE). I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn't the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing... We will cover the latest developments in the field writ large. This means we will cover any stories that affect the all the companies in this field, as well as company specific developments. Timestamps: 0:00​ - Intro 1:18​ - New Psychedelic ETF (PSIL) 5:44​ - Baltimore decriminalizes the possession of all drugs 6:53​ - Hawaii to study the benefits of psilocybin 8:29​ - Harvard University to study psychedelics 9:42​ - UCSF also decides to study psychedelics 11:24​ - MindMed (MMED / MMEDF / MMQ) announced the company's 2020 End-Year Financial results + link 12:32​ on video end year 12:50​ - MindMed files F10 File with the SEC ( important step before uplisting to the NASDAQ) 14:11​ - MindMed's 2020 conference call highlights 15:06​ - MindMed (MMED) has now filed a patent application for its 18-MC compound 17:04​ - Cybin (CYBN / CLXPF) management restructuring 19:40​ - Core One Labs (COOL ) stock updates 20:48 - Lobe Sciences ( Lobe) company updates So that's it for This Week in Psychedelic Stocks fellow psychedelic investors! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifa... ​ https://benzinga.grsm.io/thepsychedel... ​ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​ ​#MMED​​​ #MindMedStock​
Psychedelic Business News Spotlight: April 2, 2021

Psychedelic Business News Spotlight: April 2, 2021

This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.
How Field Trip Health Is Leading the Psychedelic Market Boom

How Field Trip Health Is Leading the Psychedelic Market Boom

Field Trip Health is brining psychedelics to the forefront of mental health wellness.

MindMed 2020 Conference Call and Live Discussion (MMED / MMEDF) 🚀

Hey guys! As Promised, we're live streaming the MindMed (MMED / MMEDF ) Earnings Conference Call. What we're expecting to hear and discuss later is any clinical trial updates for MindMed, updates for Project Lucy and Project Layla and perhaps their potential Nasdaq Uplisitng ! I hope you guys found some value in this and I'll keep you posted for more changes! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/news/press-release...​ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed​​​ ​#MindmedStock​​​ #MMEDNews Powered by Restream https://restream.io/ Today is MindMed's (MMED /MMEDF / MMQ) Conference call #Mindmed #MMED #MindmedConferenceCall